Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV
- 15 August 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 112 (4), 1205-1213
- https://doi.org/10.1182/blood-2008-01-135160
Abstract
Despite the demonstrated clinical efficacy of CD20 monoclonal antibody (mAb) for lymphoma therapy, the in vivo mechanisms of tumor depletion remain controversial and variable. To identify the molecular mechanisms responsible for lymphoma killing by CD20 mAb in a homologous system amenable to mechanistic studies and genetic manipulation, a mouse lymphoma model was developed using primary tumor cells from a C57BL/6 Eμ-cMyc transgenic mouse and mouse antimouse CD20 mAbs. CD20 mAb treatment of syngeneic mice with adoptively transferred lymphomas prevented tumor development or significantly prolonged mouse survival depending on tumor volume, mAb dose, and treatment timing. Cooperative FcγRIV, FcγRIII, and FcγRI interactions mediated optimal lymphoma depletion by CD20 mAb in vivo, whereas clodronate-mediated depletion of macrophages eliminated the therapeutic benefit of CD20 mAb. Although CD20 mAbs activated complement in vitro and in vivo, normal and malignant B-cell depletion was induced through C1q- and C3-independent mechanisms. Thus, the ability of CD20 mAbs to deplete malignant B cells in vivo required FcγR-dependent use of the innate mononuclear cell immune system. These findings allow for mechanism-based predictions of the biologic outcome of CD20 mAb therapy and treatment optimization.This publication has 54 references indexed in Scilit:
- Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphismBlood, 2007
- IgEb immune complexes activate macrophages through FcγRIV bindingNature Immunology, 2007
- Rituximab therapy in malignant lymphomaOncogene, 2007
- Complement in BuB/BnJ mice revisited: Serum C3 levels and complement opsonic activity are not elevatedMolecular Immunology, 2006
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid raftsBlood, 2003
- Tumor necrosis factor α release is a major biological event associated with rituximab treatmentThe Hematology Journal, 2001
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.The Journal of cell biology, 1993
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985